VBC Market Dynamics
Expert articles and analysis related to vbc market dynamics.
AI Summary — Last 30 Days
CMS under the Trump administration is pushing VBC into more operationally specific arenas: specialty episodes, chronic-care technology, and Medicaid drug purchasing, with the ACCESS model adding wearables/AI-enabled chronic care capabilities and outcome-aligned payment mechanics while the GENEROUS Model moves most-favored-nation drug pricing into Medicaid with participating states. At the same time, MA economics are tightening as MedPAC’s $76B overpayment estimate fuels pressure for payment reform and provider groups such as AMGA push back on low MA rate updates, creating a strategic squeeze for ACOs, MA-aligned groups, and specialty participants that must absorb more risk while proving measurable savings and quality. The near-term signal is clear: CMS is broadening model design beyond primary-care ACOs into specialty, pharmacy, and tech-enabled population health—rewarding organizations that can manage total cost, data infrastructure, and outcomes across settings (ACCESS model; [GENEROUS Model](https://news.google.com/rss/articles/CBMizgFBVV95cUxOOWhnN0wxZTRDYWJNSFg1Um0zS2pFMl9JZG5ZYmF6TGZsNjlIUEx6T0tfV29hck5KTm1zb1U4dHhXWDNvaUJMbjNGTmU
Related Articles
STAT+: How Trump’s latest pharma deals may undermine efforts to rein in drug costs
Analysts say private deals involve drugmakers agreeing to lower prices in Medicaid, where prices are low, in return for no price cuts in Medicare.
Three takeaways from Trump's latest drug pricing event
President Donald Trump announced voluntary drug pricing deals with nine new companies on Monday, for the first time veering outside of the original crop of companies that he singled out in letters las...
Mid-cap biotechs join Trump’s latest round of drug pricing deals
Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies.
Midsized Biotechs Strike MFN Drug Pricing Deals
Trump strikes Medicaid drug price deals with pharma firms
Trump strikes Medicaid drug price deals with pharma firms Modern Healthcare
Trump announces nine new MFN drug pricing deals
Nine new companies have announced voluntary drug pricing deals with the White House, looking to avoid industry tariffs and inclusion in two CMS pilot programs under review that are thought to be poten...
Trump strikes nine more deals with drugmakers to lower prices
President Trump on Monday announced the next round of pricing deals with drugmakers, with nine new companies making such agreements.
STAT+: 5 burning questions on Trump’s latest deals with drugmakers
Here are some of the key questions about the agreements the Trump administration has reached with drugmakers on pricing.
Sanford-North Memorial deal closes after systems ink oversight agreement
The systems agreed to 10 years of state oversight and $600 million in investments as South Dakota-based Sanford moves into the Twin Cities.
AHA Pushes Back Against Sen. Cassidy’s 340B Proposals
AHA Pushes Back Against Sen. Cassidy’s 340B Proposals HealthLeaders Media